India is still the market to beat, Morgan Stanley says

Investing.com
Updated
Mitrade
coverImg
Source: Shutterstock

Investing.com -- India’s equity market remains the preferred investment destination among emerging markets, with   Morgan Stanley   (NYSE:MS) projecting a 14% upside for the benchmark BSE Sensex by December 2025 in its base case.

Supported by robust earnings growth, macroeconomic stability, and strong domestic inflows, India’s fundamentals set it apart, even as global growth risks and near-term challenges loom.

“With strong earnings, macro stability and domestic flows, it is hard to argue against India's investment case,” analyst wrote.

India benefits from improved terms of trade, a flexible inflation-targeting regime, and steady non-portfolio foreign flows. These factors have reduced India’s beta to emerging markets to around 0.4, underpinning its premium valuation.

With earnings projected to grow at an annual rate of 18-20% over the next four to five years, India is set to capitalize on a private capital expenditure cycle, deleveraging of corporate balance sheets, and a structural rise in discretionary consumption.

A consistent source of domestic risk capital ensures that local demand for equities remains robust, mitigating external volatility and supporting equity valuations.

Morgan Stanley’s base case factors a continued fiscal consolidation, rising private investment, and a favourable real growth-to-real interest rate gap.

Combined with stable oil prices, an absence of U.S. recession, and a modest reduction in interest rates, these factors are expected to propel Sensex earnings to compound at 17.3% annually through FY27. The brokerage’s forecast remains 15% above consensus for this period.

The Indian market is expected to be a stock pickers’ market, away from the one driven by top down or macro factors since COVID years.

Morgan Stanley says to overweight on cyclicals such as financials, consumer discretionary, industrials, and technology, while have an underweight on other sectors. Small and mid-cap stocks are favoured over large caps, reflecting confidence in domestic growth drivers.

 

* The content presented above, whether from a third party or not, is considered as general advice only.  This article should not be construed as containing investment advice, investment recommendations, an offer of or solicitation for any transactions in financial instruments.

goTop
quote
Do you find this article useful?
Related Articles
placeholder
2 Popular AI Stocks to Sell Before They Fall 65% and 73%, According to Certain Wall Street AnalystsPalantir Technologies (NASDAQ: PLTR) and Tesla (NASDAQ: TSLA) were two of the most popular stocks among retail investors last year as measured by net inflows. But most Wall Street
Author  The Motley Fool
3 hours ago
Palantir Technologies (NASDAQ: PLTR) and Tesla (NASDAQ: TSLA) were two of the most popular stocks among retail investors last year as measured by net inflows. But most Wall Street
placeholder
AMD Reports Record Q4 Revenue, Shares Plunge 9% on Data Center MissAMD, a global semiconductor giant, saw its stock price fluctuate dramatically after releasing its Q4 2024 earnings report, despite surpassing consensus estimates on both the top and bottom lines. The
Author  TradingKey
5 hours ago
AMD, a global semiconductor giant, saw its stock price fluctuate dramatically after releasing its Q4 2024 earnings report, despite surpassing consensus estimates on both the top and bottom lines. The
placeholder
Microsoft Shares Slip on "Soft" Azure Revenue. Is This a Buying Opportunity in the Stock?Microsoft (NASDAQ: MSFT) shares fell after revenue from its Azure cloud computing platform came in at the low end of its prior guidance, although the unit continues to be company's
Author  The Motley Fool
Yesterday 03: 21
Microsoft (NASDAQ: MSFT) shares fell after revenue from its Azure cloud computing platform came in at the low end of its prior guidance, although the unit continues to be company's
placeholder
Novo Nordisk Q4 2024 Results: Will Wegovy Continue to Shine?TradingKey - One of the biggest trends in the healthcare space over the past few years has been the rise of so-called GLP-1 drugs.These can help treat type 2 diabetes and obesity but one of the other
Author  TradingKey
Yesterday 02: 41
TradingKey - One of the biggest trends in the healthcare space over the past few years has been the rise of so-called GLP-1 drugs.These can help treat type 2 diabetes and obesity but one of the other
placeholder
Where Will Nvidia Stock Be in 3 Years?If you held on to Nvidia (NASDAQ: NVDA) stock for the last three years, you are probably laughing all the way to the bank. A $10,000 bet made in early 2022 would be worth almost $5
Author  The Motley Fool
Feb 03, Mon
If you held on to Nvidia (NASDAQ: NVDA) stock for the last three years, you are probably laughing all the way to the bank. A $10,000 bet made in early 2022 would be worth almost $5